Hepatitis C Neutralizing Antibodies Targeting E2 Epitope II
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C virus (HCV) infection are limited by high genetic diversity, expensive direct-acting antiviral drugs, and the lack of effective vaccines, with recurrence of HCV infection being a significant issue post-liver transplantation.
Innovation Solution
Development of neutralizing antibodies specifically binding to HCV E2 protein Epitope II, comprising specific heavy and light chain variable region sequences, to inhibit HCV infection and potentially prevent recurrence in liver transplant patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct-acting antiviral drugs are used to treat HCV infection, then treatment effectiveness is improved, but treatment cost increases significantly
Solution Approach 1:
The patent develops neutralizing antibodies as an alternative to expensive direct-acting antiviral drugs. These antibodies are designed to be cost-effective while maintaining treatment effectiveness, providing a more accessible therapy option for HCV infection without requiring the high costs associated with current antiviral medications.
Solution Approach 2:
The patent uses neutralizing antibodies as intermediary molecules that bind to HCV particles and block infection. These antibodies serve as a mediating substance between the immune system and the virus, providing therapeutic effect through a different mechanism than direct-acting antivirals, potentially reducing treatment costs while maintaining effectiveness.
2Reliability
If combination therapy with pegylated interferon and ribavirin is used, then treatment success rate is improved, but treatment duration and side effects increase
Solution Approach 1:
The patent extracts and isolates the neutralizing function from complex combination therapies. By developing specific neutralizing antibodies that directly target HCV, the invention removes the need for prolonged combination therapy with interferon and ribavirin, achieving viral neutralization through a single targeted mechanism rather than multiple drugs administered over extended periods.
Solution Approach 2:
The patent changes the therapeutic parameter from long-duration combination chemotherapy to short-duration or single-dose neutralizing antibody administration. This parameter change maintains or improves treatment success while dramatically reducing treatment duration and associated side effects by using antibodies with high neutralizing potency.
3Reliability
If HCV-specific antibody products are developed, then prevention of recurrence in liver transplant patients is improved, but development complexity increases
Solution Approach 1:
The patent develops neutralizing antibodies in advance that can be stored and administered prophylactically to liver transplant patients. By preparing these antibodies before transplant and having them ready for immediate administration, the invention prevents HCV recurrence without requiring complex development efforts during the critical post-transplant period.
Solution Approach 2:
The patent develops neutralizing antibodies with broad specificity that can function both as treatment for active HCV infection and as prophylaxis against recurrence in transplant patients. This multi-functional antibody product simplifies development by creating a single versatile therapeutic that addresses multiple clinical needs rather than requiring separate products for treatment and prevention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively neutralize HCV genotype 1a infectivity in cell culture systems, offering a promising treatment and prevention option for HCV infection, including reducing the risk of recurrence in liver transplant patients.
Implementation Method 1
Disclosed herein is an HCV neutralizing antibody binding specifically to HCV E2 protein Epitope II (EPII)
Data Source
AI summary
A specific epitope on the surface of the hepatitis C virus that induces a neutralizing antibody response in vivo and neutralizing monoclonal antibodies that bind specifically to the epitope are disclosed. The antibodies block hepatitis C virus from infecting cells.